ArticleJournal of medical Internet research2026
Digital Behavioral Infrastructure for Glucagon-Like Peptide-1 Pharmacotherapy: Viewpoint on Persistence, Tolerability, and Postcessation Durability.
Article in Journal of medical Internet research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) induce clinically meaningful weight loss, but their real-world impact is constrained by poor medication persistence, treatment-limiting gastrointestinal adverse effects, and rapid weight regain after cessation. These limitations may be structural rather than incidental: GLP-1 RAs powerfully address appetite biology but do not build the behavioral skills, environmental supports, and routines needed to sustain outcomes when biological pressures revert to baseline. This viewpoint argues that theory-based digital health companion programs are best understood as structural complements to glucagon-like peptide-1 (GLP-1) therapy rather than optional adjuncts, and it articulates a testable mechanistic hypothesis: a pharmacologically enabled "habit window." We map theoretical determinants from the social cognitive theory (SCT) and behavioral economics (BE) to classes of digital intervention across 3 problems (medication persistence, tolerability, and postcessation durability) and grade the supporting evidence as established, observational, or hypothesized. For each problem, we link candidate SCT- and BE-informed mechanisms (such as self-efficacy and enactive mastery, present bias, defaults, and loss aversion) to specific digital intervention classes and to the studies needed to test them. Because reduced appetitive drive may free cognitive resources and lower the need for food-related self-control, GLP-1 therapy may open a privileged window in which habit formation is easier. Supporting evidence is drawn from adjacent behavioral trials, combined pharmacological and lifestyle trials, and observational engagement data; the observational data are hypothesis generating and subject to selection effects. Digital behavioral infrastructure may help translate the biological effects of GLP-1 therapy into durable behavioral and environmental change, but the "habit window" remains a hypothesis requiring prospective and randomized testing. We outline a research agenda prioritizing randomized trials with postcessation follow-up and mechanistic mediation studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.